We are live on ! Find out more
QM

QVIDTVM Management Portfolio holdings

AUM $76.6M Turnover 13.33%
1-Year Est. Return 33.48%
This Fund
S&P 500
This Quarter Est. Return
+35.5%
1 Year Est. Return
+33.48%
3 Year Est. Return
+19.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76.6M
AUM Growth
-$4.77M
Cap. Flow
-$19.2M
Cap. Flow %
-25.12%
Top 10 Hldgs %
99.22%
Holding
15
New
1
Increased
3
Reduced
10
Closed
1
Avg Time Held
1.4 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
ORCL icon
Oracle
ORCL
+$3.27M
2
ARE icon
Alexandria Real Estate Equities
ARE
+$2.03M
3
AMRZ icon
Amrize Ltd
AMRZ
+$1.62M
4
OCTV icon
Octave Intelligence
OCTV
+$1.06M

Sector Composition

Rank Sector Weight
1 Healthcare 34.86%
2 Communication Services 17.54%
3 Materials 17.21%
4 Technology 12.12%
5 Consumer Discretionary 7.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
BIO icon
1
Bio-Rad Laboratories Class A
BIO
$9.46B
$19.4M 25.39%
66,243
-17,489
-21% -$4.96M
2023 Q3
11 quarters
NBIS icon
2
Nebius Group N.V.
NBIS
$46.7B
$13.4M 17.54%
48,657
-12,021
-20% -$2.38M
2025 Q4
2 quarters
AMRZ icon
3
Amrize Ltd
AMRZ
$20.7B
$13.2M 17.21%
247,391
+29,935
+14% +$1.62M
2025 Q4
2 quarters
ORCL icon
4
Oracle
ORCL
$396B
$8.35M 10.9%
56,970
+18,068
+46% +$3.27M
2026 Q1
1 quarter
SOLV icon
5
Solventum
SOLV
$14.6B
$6.87M 8.97%
89,033
-176,582
-66% -$12.9M
2024 Q1
9 quarters
ZGN icon
6
Zegna
ZGN
$3.45B
$5.93M 7.75%
455,804
-70,089
-13% -$904K
2024 Q3
7 quarters
ARE icon
7
Alexandria Real Estate Equities
ARE
$6.93B
$4.36M 5.69%
82,470
+42,470
+106% +$2.03M
2025 Q4
2 quarters
BRCC icon
8
BRC Inc
BRCC
$143M
$3.28M 4.28%
295,314
-44,754
-13% -$554K
2023 Q1
13 quarters
OCTV icon
9
Octave Intelligence
OCTV
$5.52B
$937K 1.22%
+57,466
New +$1.06M
2026 Q2
0 quarters
WAB icon
10
Wabtec
WAB
$48.7B
$202K 0.26%
750
-2,020
-73% -$534K
2021 Q4
18 quarters
XRAY icon
11
Dentsply Sirona
XRAY
$1.67B
$201K 0.26%
18,929
-366,480
-95% -$4M
2024 Q1
9 quarters
PM icon
12
Philip Morris
PM
$314B
$186K 0.24%
1,026
-53
-5% -$9.19K
2026 Q1
1 quarter
LAB icon
13
Standard BioTools
LAB
$252M
$183K 0.24%
222,000
-7,338
-3% -$6.93K
2025 Q4
2 quarters
HRB icon
14
H&R Block
HRB
$5.88B
$32.1K 0.04%
844
-22,411
-96% -$781K
2026 Q1
1 quarter
RTO icon
15
Rentokil
RTO
$10.6B
– –
-6,879
Closed -$217K –

Similar funds

QVIDTVM Management's Q2 2026 Portfolio in Review

As of Q2 2026, QVIDTVM Management held 15 positions worth $76.6M, down 5.9% from $81.4M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

QVIDTVM Management withdrew a net $19.2M in Q2 2026, closing 1 position and reducing 10 holdings. Its most notable exit was Rentokil, an estimated $217K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 56% a quarter earlier, followed by Communication Services and Materials.

Against the trend, QVIDTVM Management opened a new position in Octave Intelligence worth $937K.

  • QVIDTVM Management's largest Q2 2026 buy was Octave Intelligence: 57,466 shares worth $937K.
  • QVIDTVM Management added most to Oracle in Q2 2026, an estimated $3.27M increase.
  • QVIDTVM Management's biggest Q2 2026 reduction was Solventum, cutting an estimated $12.9M.
  • QVIDTVM Management fully exited Rentokil in Q2 2026, selling an estimated $217K.
  • QVIDTVM Management's ten largest holdings make up 99% of its $76.6M portfolio in Q2 2026.
  • QVIDTVM Management opened 1 new position and closed 1 in Q2 2026.
  • QVIDTVM Management's portfolio value fell 5.9% quarter-over-quarter to $76.6M.

Based on QVIDTVM Management's 13F filing for Q2 2026, filed 13 Aug 2026.